We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Events

28 Jan 2019 - 01 Feb 2019

Radium-223 Dichloride Should be Used with Caution

By Medimaging International staff writers
Posted on 29 Aug 2018
Print article
Image: Research suggests radioctive radium may increase mortality and fracture risk (Photo courtesy of Adobe Stock).
Image: Research suggests radioctive radium may increase mortality and fracture risk (Photo courtesy of Adobe Stock).
The European Medicines Agency (EMA; London, United Kingdom) recommends that use of the novel radiopharmaceutical radium-223 dichloride (Xofigo) in metastasized prostate cancer (PC) should be restricted.

The recommendation, issued by the EMA pharmacovigilance risk assessment committee (PRAC), follows reports of increased deaths and fractures in an ongoing clinical trial, during which patients receiving Xofigo in conjunction with abiraterone acetate and prednisone/prednisolone died 2.6 months earlier on average than those given abiraterone acetate and prednisone/prednisolone together with a placebo. In addition, 29% of patients who received the Xofigo combination suffered fractures, compared with 11% of patients in the placebo group.

PRAC suggests that Xofigo should not be used in patients with no symptoms, or in those with a lower number of osteoblastic bone metastases. The agency also stated that radium-223 dichloride should not be used with other systemic cancer therapies, except for hormone therapies. Patients should also be carefully assessed for risk for fractures before, during, and after treatment, and preventive measures, such as the use of bisphosphonates or denosumab as agents to increase bone strength, should be considered before treatment with Xofigo is started or resumed.

“Patient safety is our top priority. We are therefore unblinding the study to thoroughly analyze the data,” said Mike Devoy, chief medical officer at Bayer, the manufacturer of Xofigo. “It is important to note that, based on available data from previous trials as well as real-world use, the benefit-risk profile of Xofigo in its approved indication remains favorable.”

Xofigo is a drug designed to treat advanced castration-resistant PC by binding with minerals to deliver radiation directly to metastatic bone tumors, limiting the damage to the surrounding normal tissues. It is not recommended that patients taking Xofigo should undergo chemotherapy at the same time, as the combination of drugs can cause bone marrow activity to decrease, resulting in fewer red blood cells, white blood cells, and platelets.

Related Links:
European Medicines Agency


Print article
Italray
Clear Image Devices

Channels

Copyright © 2000-2018 Globetech Media. All rights reserved.